Exploratory Analysis of $\textit{TP53}$ Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

Autor: Parkinson, CA, Gale, D, Piskorz, AM, Biggs, H, Hodgkin, C, Addley, H, Freeman, S, Moyle, P, Sala, E, Sayal, K, Hosking, K, Gounaris, I, Jimenez-Linan, M, Earl, HM, Qian, W, Rosenfeld, N, Brenton, JD

$\textbf{Background:}$ Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations may provide a minimally invasive means to dynamically assess tumour burden and response to treatment in cancer patients. Somatic $\textit{TP53}$ mutat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afacd17cc1d6d37f3a363f790600922b

Prognostic gene expression signature for high-grade serous ovarian cancer

Autor: Millstein, J, Budden, T, Goode, EL, Anglesio, MS, Talhouk, A, Intermaggio, MP, Leong, HS, Chen, S, Elatre, W, Gilks, B, Nazeran, T, Volchek, M, Bentley, RC, Wang, C, Chiu, DS, Kommoss, S, Leung, SCY, Senz, J, Lum, A, Chow, V, Sudderuddin, H, Mackenzie, R, George, J, AOCS Group, Fereday, S, Hendley, J, Traficante, N, Steed, H, Koziak, JM, Köbel, M, McNeish, IA, Goranova, T, Ennis, D, Macintyre, G, Silva De Silva, D, Ramón Y Cajal, T, García-Donas, J, Hernando Polo, S, Rodriguez, GC, Cushing-Haugen, KL, Harris, HR, Greene, CS, Zelaya, RA, Behrens, S, Fortner, RT, Sinn, P, Herpel, E, Lester, J, Lubiński, J, Oszurek, O, Tołoczko, A, Cybulski, C, Menkiszak, J, Pearce, CL, Pike, MC, Tseng, C, Alsop, J, Rhenius, V, Song, H, Jimenez-Linan, M, Piskorz, AM, Gentry-Maharaj, A, Karpinskyj, C, Widschwendter, M, Singh, N, Kennedy, CJ, Sharma, R, Harnett, PR, Gao, B, Johnatty, SE, Sayer, R, Boros, J, Winham, SJ, Keeney, GL, Kaufmann, SH, Larson, MC, Luk, H, Hernandez, BY, Thompson, PJ, Wilkens, LR, Carney, ME, Trabert, B, Lissowska, J, Brinton, L, Sherman, ME, Bodelon, C, Hinsley, S, Lewsley, LA, Glasspool, R, Banerjee, SN, Stronach, EA, Haluska, P, Ray-Coquard, I, Mahner, S, Winterhoff, B, Slamon, D, Levine, DA, Kelemen, LE, Benitez, J, Chang-Claude, J, Gronwald, J, Wu, AH, Menon, U, Goodman, MT, Schildkraut, JM, Wentzensen, N, Brown, R, Berchuck, A, Chenevix-Trench, G, DeFazio, A, Gayther, SA, García, MJ, Henderson, MJ, Rossing, MA, Beeghly-Fadiel, A, Fasching, PA, Orsulic, S, Karlan, BY, Konecny, GE, Huntsman, DG, Bowtell, DD, Brenton, JD, Doherty, JA, Pharoah, PDP, Ramus, SJ

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74bdd0831511aa30c41cb97076462cf9

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer.

Autor: Nelson BH; Deeley Research Centre, BC Cancer, Victoria, Canada., Hamilton PT; Deeley Research Centre, BC Cancer, Victoria, Canada., Phung MT; School of Public Health, University of Michigan, Ann Arbor, United States of America., Milne K; Deeley Research Centre, BC Cancer, Victoria, Canada., Harris B; Deeley Research Centre, BC Cancer, Victoria, Canada., Thornton S; Deeley Research Centre, BC Cancer, Victoria, Canada., Stevens DL; Deeley Research Centre, BC Cancer, Victoria, Canada., Kalaria S; Deeley Research Centre, BC Cancer, Victoria, Canada., Singh K; Deeley Research Centre, BC Cancer, Victoria, Canada., Laumont CM; Deeley Research Centre, BC Cancer, Victoria, Canada., Moss E; Deeley Research Centre, BC Cancer, Victoria, Canada., Alimujiang A; School of Public Health, University of Michiagn, Ann Arbor, United States of America., Meagher NS; School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, Australia., Bolithon A; School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, Australia., Fereday S; Cancer Genetics and Genomics Laboratory, Peter MaCallum Cancer Centre, Melbourne, Australia., Kennedy CJ; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia., Hendley J; Cancer Genetics and Genomics Laboratory, Peter MaCallum Cancer Centre, Melbourne, Australia., Ariyaratne D; Cancer Genetics and Genomics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia., Alsop K; Cancer Genetics and Genomics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia., Traficante N; Cancer Genetics and Genomics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia., Goode EL; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, United States of America., Karnezis AN; Department of Pathology, UCD School of Medicine, Sacramento, United States of America., Shen H; Epigenetics, Van Andel Institute, Grand Rapids, United States of America., Richardson J; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, United States of America., McKinnon Deurloo C; Patient Advocate, United States of America., Chase A; Patient Advocate, United States of America., Grout B; Patient Advocate, United States of America., Doherty JA; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, United States of America., Harris HR; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, United States of America., Cushing-Haugen KL; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Anglesio MS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Heinze K; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Huntsman D; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Talhouk A; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Hanley GE; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Alsop J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom., Jimenez-Linan M; Department of Histopathology, Addenbrooke's Hospital, Cambridge, United Kingdom., Pharoah PD; Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, United States of America., Boros J; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia., Brand AH; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia., Harnett PR; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia., Sharma R; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia., Hecht JL; Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America., Sasamoto N; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and, Brigham and Women's Hospital and Harvard Medical School, Boston, United States of America., Terry KL; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and, Brigham and Women's Hospital and Harvard Medical School, Boston, United States of America., Karlan BY; Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, United States of America., Lester J; Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, United States of America., Carney ME; Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, United States of America., Goodman MT; Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, United States of America., Hernandez BY; University of Hawaii Cancer Center, Honolulu, United States of America., Wilkens LR; University of Hawaii Cancer Center, Honolulu, United States of America., Behrens S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Turzanski Fortner R; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlang, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany., Bisinotto C; Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Candido Dos Reis FJ; Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Ghatage P; Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada., Köbel M; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada., Elishaev E; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States of America., Modugno F; Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, United States of America., Cook LS; Epidemiology, School of Public Health, University of Colorado, Aurora, United States of America., Le ND; Cancer Control Research, BC Cancer Agency, Vancouver, Canada., Gentry-Maharaj A; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom., Menon U; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom., García MJ; Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC-UAM, Madrid, Spain., Rodriguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Farrington KM; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada., Kelemen LE; Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, United States of America., Kommoss S; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany., Staebler A; Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany., Garsed DW; Cancer Genetics and Genomics Laboratory, Peter MaCallum Cancer Centre, Melbourne, Australia., Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Piskorz AM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Bowtell DD; Cancer Genetics and Genomics Laboratory, Peter MaCallum Cancer Centre, Melbourne, Australia., DeFazio A; The Daffodil Centre, The University of Sydney, Sydney, Australia., Ramus SJ; School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, Australia., Pike MC; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States of America., Pearce CL; School of Public Health, University of Michigan, Ann Arbor, United States of America.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Oct 29. Date of Electronic Publication: 2024 Oct 29.

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.

Autor: Crispin-Ortuzar M; Department of Oncology, University of Cambridge, Cambridge, UK. mc973@cam.ac.uk.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK. mc973@cam.ac.uk., Woitek R; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.; Centre for Medical Image Analysis and AI (MIAAI), Danube Private University, Krems, Austria., Reinius MAV; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Moore E; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Beer L; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria., Bura V; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK., Rundo L; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.; Department of Information and Electrical Engineering and Applied Mathematics, University of Salerno, Fisciano, SA, Italy., McCague C; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Ursprung S; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK., Escudero Sanchez L; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK., Martin-Gonzalez P; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Mouliere F; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Department of Pathology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Chandrananda D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Morris J; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Goranova T; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Piskorz AM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Singh N; Department of Cellular Pathology, Barts Health NHS Trust, London, UK., Sahdev A; Department of Radiology, Barts Health NHS Trust, London, UK., Pintican R; 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania.; Department of Radiology, County Clinical Emergency Hospital, Cluj-Napoca, Romania., Zerunian M; Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Rome, Italy., Rosenfeld N; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Addley H; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Jimenez-Linan M; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Markowetz F; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Sala E; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Dipartimento di Scienze Radiologiche ed Ematologiche, Universita Cattolica del Sacro Cuore, Rome, Italy.; Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Western Balkans University, Tirana, Albania., Brenton JD; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Publikováno v: Nature communications [Nat Commun] 2023 Oct 24; Vol. 14 (1), pp. 6756. Date of Electronic Publication: 2023 Oct 24.

Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.

Autor: Smith P; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Bradley T; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Gavarró LM; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Goranova T; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Ennis DP; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK., Mirza HB; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK., De Silva D; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Piskorz AM; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Sauer CM; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Al-Khalidi S; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Funingana IG; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Reinius MAV; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Giannone G; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK., Lewsley LA; CRUK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Stobo J; CRUK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., McQueen J; CRUK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Bryson G; Department of Histopathology, Queen Elizabeth University Hospital, Glasgow, UK., Eldridge M; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Macintyre G; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.; Centro Nacional de Investigaciones Oncológicas, Madrid, Spain., Markowetz F; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK., Brenton JD; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK. james.brenton@cruk.cam.ac.uk.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. james.brenton@cruk.cam.ac.uk., McNeish IA; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK. i.mcneish@imperial.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2023 Sep 26; Vol. 14 (1), pp. 5992. Date of Electronic Publication: 2023 Sep 26.